Privia Health Group, Inc. PRVA 深 滬
等待開盤 07-17 09:30:00 美东时间
20.58
-0.060
-0.29%
華盛通- 最 高20.83
- 今 開20.71
- 成交量 69.90万股
- 最 低 20.355
- 昨 收 20.64
- 總市值 25.11亿
- 52周最高 26.0899
- 市盈率 靜 179.74
- 換手率 0.57%
- 52周最低 16.47
- 委 比 -36.45%
- 總股本 1.22亿
- 歷史最高 50.77
- 量 比 0.80
- 振 幅 2.30%
- 歷史最低 15.92
- 每 手 1
- 風險率 2.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Privia Health to Report Second Quarter 2025 Results on Thursday, August 7
Privia Health Group will release its second-quarter and six-month financial results before market open on August 7, 2025. The press release will be available on the Company’s Investor Relations website at ir.priviahealth.com by 7:00 am ET. A conference call will be held at 8:00 am ET to discuss the results and future outlook.
07-10 13:00
Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors
Privia Health Group announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. Berberian, a technology strategist with over 30 years of experience in digital transformation and cybersecurity, will also join the Audit Committee. His expertise is expected to support Privia's growth in building scalable provider networks across the U.S. Berberian previously served as Chief Information and Technology Officer a...
07-08 13:00
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Prenetics Global (NASDAQ:PRE) shares moved upwards by 17.8% to $9.45 d...
06-13 20:11
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
美股大行评级 | 潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
05-28 09:04
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $24
Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:PRVA) with a Equal-Weight and raises the price target from $23 to $24.
05-28 00:19
Privia Health Group shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.
Privia Health Group shares are trading higher after the company reported better...
05-08 22:51
Privia Health Gr Affirms FY2025 Sales Guidance of $1.80B-$1.90B vs $3.22B Est
Privia Health Gr (NASDAQ:PRVA) affirms FY2025 sales outlook from $1.80 billion-$1.90 billion to $1.80 billion-$1.90 billion vs $3.22 billion estimate.
05-08 18:03
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE:SRE) is likely to report qua...
05-08 16:33
美股大行评级 | 潜在涨幅684.71%！Verve Therapeutics获Canaccord Genuity升目标价至39美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119185980869894144.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Verve Therapeutics(VERV)"买入"评级，目标价从32美元升至39美元</p> <p>• HC Wainwright & Co.：维持Verve Ther
04-16 09:45
